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Abstract
Background: Orofacial granulomatosis (OFG) is characterized by granulomatous in-
flammation of the soft tissues of maxillofacial region. We explored OFG patients from 
10 different Italian centers and summarized the most recent literature data.
Methods: A review of patients with OFG was carried out. An extensive online litera-
ture search was performed to identify studies reporting diagnosis and management 
of OFG.
Results: Thirty- nine patients were recruited between January 2018 and February 
2020. Most of them (97.4%) displayed involvement of the lips, and 28.2% suffered 
from Melkersson- Rosenthal syndrome. Two patients received diagnosis of CD and 
2190  |    GALDIERO Et AL.
1  |  BACKGROUND
Orofacial granulomatosis (OFG) is a rare disorder characterized by 
persistent and/or recurrent labial enlargement and chronic non- 
caseous granulomatosis involving the soft tissue of the oral and 
maxillofacial regions.1 This term includes the variants Melkersson- 
Rosenthal syndrome (MRS) and granulomatous cheilitis of Miescher 
(GCM).2
OFG, MRS, and GCM have been heterogeneously described 
throughout the years by the scientific literature. In many cases, their 
clinical characteristics overlap and it is unclear how to distinguish 
one patient of sarcoidosis, suggesting secondary OFG. Oral aphthosis and cervical 
lymphadenopathy were also described. The mean diagnostic delay was 3.4 years. 
Histological evaluation was performed in 34/39 patients (87.2%); non- caseating gran-
ulomas were found in 73.5% of them. Neurological symptoms (28.2%), gastrointes-
tinal symptoms in absence of overt inflammatory bowel disease (IBD) (20.5%), and 
atopy (35.9%) were also identified. Therapeutic approaches varied among the cent-
ers. Steroids (51.3%) were used with good or partial results. Anti- TNF- α and anti- IgE 
monoclonal antibodies were used in 6 (15.4%) and 1 (2.6%) patients, respectively, with 
variable results. Surgery was the choice for 2 patients with good response.
Conclusions: OFG is a rare and neglected disease showing multiple clinical pheno-
types. While early diagnosis is crucial, management is difficult and highly dependent 
on the expertise of clinicians due to the lack of international guidelines. There is a need 
to establish registry databases and address challenges of long- term management.
K E Y W O R D S
granulomatous cheilitis, Italian registries, Melkersson- Rosenthal syndrome, orofacial 
granulomatosis
G R A P H I C A L  A B S T R A C T
This article provides a description of clinical features of 39 patients with OFG, a granulomatous inflammatory disease of soft tissues of 
maxillofacial regions. In the majority of patients, lip swelling is the first clinical manifestation of disease. Intralesional corticosteroids are a 
cornerstone of treatment and show the highest response rate in these patients. Abbreviations: DMARDs, disease- modifying anti- rheumatic 
drugs; OFG, orofacial granulomatosis
Abbreviation: DMARDs, disease-modifying anti-rheumatic drugs; OFG, orofacial granulomatosis
    |  2191GALDIERO Et AL.
the three different variants. In this article, we use the term GCM 
when the swelling involves just one or both lips and MRS when OFG 
is associated with cranial nerve involvement.
The exact prevalence of OFG is unknown, but it is considered a 
rare disease. The increased incidence of the last few years is likely 
due to the improved knowledge, but the condition still remains a ne-
glected entity.3 Secondary OFG can occur in the context of a systemic 
granulomatous disease such as Crohn's disease (CD) or sarcoidosis. In 
the absence of other systemic pathologies, OFG is defined as idio-
pathic. OFG was proposed as a variant of CD with the distinct feature 
as localizing to the oral cavity. Indeed, a considerable percentage of 
patients with OFG (about 40% in pediatrics and 20%– 50% in adults) 
is diagnosed as CD.4 These data could be underestimated, since intes-
tinal involvement can be asymptomatic at the beginning.5 Moreover, 
OFG can precede by many years the onset of intestinal symptoms and 
therapy can also partially mask the intestinal involvement.6,7 Further 
studies, involving a larger number of patients, are required to clarify 
whether CD and OFG represent two distinct clinical entities or not. 
In the clinical practice, CD should be suspected in all patients with 
OFG and patients suffering from gastrointestinal symptoms need to 
undergo second- level investigations.8 Oral ulcers, increased inflam-
matory markers, changes in blood counts, and pediatric onset of OFG 
are the main risk factors for progression to CD.4
International guidelines on diagnosis and therapy are missing, 
thus making the management of the disease often dependent on the 
single- center experience or based on expert opinion.
The objective of the present study was to describe the clinical 
presentation, treatment, and outcome of patients with OFG from 10 
Italian centers and summarize the available literature regarding the 
diagnosis and treatment of OFG.
2  |  METHODS
Patients from the allergy, immunology, or dermatology clinics of 10 
different Italian reference centers1 who were diagnosed with orofa-
cial granulomatosis were included in the study. Data were retrospec-
tively collected from medical records. Due to the absence of 
diagnostic criteria, diagnosis of OFG was based on clinical symptoms 
(persistent and/or recurrent enlargement involving the soft tissue of 
the oral and maxillofacial regions), exclusion of systemic granuloma-
tous diseases (sarcoidosis, tuberculosis, IBD), and histological data 
(chronic non- caseous granulomatosis) if available. The study was ap-
proved by the Ethics Committee (protocol number 319/17— University 
of Naples Federico II, Naples, Italy) and conducted in compliance 
with the Helsinki Declaration.
An extensive review of the medical literature was conducted by 
searching all available clinical data up to April 2020 in several da-
tabases using a combination of MESH terms related to OFG (159 
References), MRS (230 References), and GCM (24 References) back 
to the year 1965.
Among all, 91 full- text articles have been accessed. The remain-
ing articles were excluded from the review because of inaccessibil-
ity of full- text article. The oldest article retrieved was published in 
1965, the most recent in 2020.
3  |  RESULTS
A total of 39 patients with OFG were recruited in 10 Italian cent-
ers between January 2018 and February 2020. Of 39 patients, 18 
(46.2%) were males. The mean age at diagnosis was 45.3 (±17.5) 
years, whereas the mean age of onset was 41.9 (±17.26) with a mean 
diagnostic delay of 3.4 years (±3.6). None of the patients presented 
familial history for OFG or its variants. Among all the patients, 28.2% 
suffered from MRS. Almost all (97.4%) displayed persistent swelling 
of one or both lips, which was the most frequent localization and, 
in 11 (28.2%) of them, the lip was the only localization, suggesting 
the diagnosis of GCM. Additionally, 7 patients (17.9%) also presented 
oral aphthosis and 6 patients (15.4%) cervical lymphadenopathy. 
Histological evaluation was available for 34/39 patients (87.2%), and 
in 25 (73.5%), non- caseating granulomas were found. In the remain-
ing 9 patients (26.5%), chronic non- specific inflammation was de-
scribed, without pathognomonic diagnostic elements.
Eleven patients (28.2%) also presented neurological symptoms 
(hemicranias, dizziness). Eight (20.5%) patients complained gastro-
intestinal symptoms (diarrhea, abdominal pain), even in absence of 
IBD. Food or inhalant allergic sensitization was found in 9 patients 
(23.1%), by skin prick test (SPT) or specific IgE for food or inhalant 
allergens. In 5 out of these 9 patients, a history of clinical manifes-
tations of allergic rhinitis or asthma was described. In 3 out of these 
9 patients, no clinical manifestations of allergy were identified and 
raised specific IgE levels were found in the course of the diagnos-
tic work- up. The remaining patient only displayed elevated total 
IgE levels in the absence of any clinical manifestation or specificity. 
Moreover, positive patch tests were found in 5 patients (12.8%), with 
only one patient referring symptoms (contact allergic dermatitis). Of 
these patients, one patient with allergic rhinitis and the patient with 
contact dermatitis also displayed increased levels of circulating eo-
sinophils (690 and 750/µl, respectively). Among these five patients, 
one was positive to nickel and underwent elimination diet without 
any clinical response.
Six patients (15.4%) displayed positive anti- nuclear antibodies 
(titer>1:160); in this group, only one patient displayed a clinical history 
of stroke together with the positivity for antiphospholipid antibodies 
 1Department of TranslationalMedicalSciences, Allergy and ClinicalImmunology, 
University of Naples Federico II, Naples; Allergy Unit, San GiacomoHospital, Novi Ligure, 
Alessandria; Dermatology and Allergy Unit, Surgical, Medical and DentalDepartment of 
MorphologicalSciences related to Transplant, Oncology and Regenerative Medicine, 
University of Modena and Reggio Emilia, Modena; Department of Medicine, University 
of Padova, Padova; Experimental and Clinical Medicine Department, University of 
Florence, Florence; Division of Allergy and ClinicalImmunology, University of Salerno, 
Salerno; Department of Emergency and OrganTransplantation, School of Allergology and 
ClinicalImmunology, University of Bari Aldo Moro, Bari; Department of MedicalSciences, 
Allergy and ClinicalImmunology, University of Turin& AO Mauriziano "Umberto I", Turin; 
Ospedali Riuniti Villa Sofia- Cervello, Unità Operativa Complessa di Patologia Clinica, 
Palermo, Department of MedicalSciences and Public Health, University of Cagliari, 
Monserrato
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(lupus anticoagulant, anti- cardiolipin, anti- β2- glycoprotein I IgM) and 
reduced C3 and C4 levels.9 The remaining 5 patients did not show 
any clinical sign or symptom suggestive of systemic autoimmune dis-
ease. Immunofluorescence pattern was explored only in 2 patients 
(one had nuclear and one had speckled pattern). Serum comple-
ment levels were normal in all patients, except the patient described 
above. Five patients (12.8%) presented hepatomegaly with normal 
liver function. Two cases presented periodontal disease (5.1%). Two 
patients received diagnosis of CD (5.1%) and one patient (2.6%) of 
sarcoidosis, suggesting secondary OFG. The clinical characteristics 
of the study population are shown in Table 1.
Therapeutic approaches vary among the centers and are sum-
marized in Table 2. We have classified the response to therapies in 
three possible outcomes: (i) good response when symptoms disap-
peared; (ii) partial response when patients had an improvement; and 
(iii) no response when the symptoms were unchanged after therapy. 
Intralesional steroids (triamcinolone acetonide, 40 mg/ml at 1 up to 
4- week intervals) were used in 12 patients, and gave partial results in 
more than 60% of them. Systemic glucocorticoids (GCs) were the most 
commonly used drugs (51.3%) with good or partial results. Among oral 
steroids, betamethasone (1– 2 mg/day) was used in 5 patients and gave 
the best results (100% good response). Prednisone (15– 60 mg/day) 
and deflazacort (15 mg/day) were also used with variable results (50% 
partial responses). In 5 patients (12.8%) anti- TNF- α monoclonal anti-
bodies were used. In more details, infliximab (5 mg/kg i.v. at 8- week 
intervals) or adalimumab (40 mg s.c. at two- week intervals) was ad-
ministered, with partial response. The anti- IL- 6 monoclonal antibody 
sarilumab (200 mg s.c. at two- week intervals) was used in a single re-
fractory case without any therapeutic effect. In one patient, based on 
high circulating levels of total IgE, the anti- IgE monoclonal antibody 
omalizumab (300 mg s.c. monthly for 6 months) was used, with good 
clinical response but relapse upon drug discontinuation.10 Lip reduc-
tion surgery was the choice for two patients with good and persistent 
results.11 No response to anti- H1 drugs was observed.
4  |  DISCUSSION
4.1  |  Definitions, epidemiology, and clinical 
features
The term OFG was introduced in 1985 by Wiesenfeld to encompass 
the previously described disease entities of GCM and MRS.12 The 
most frequent clinical feature of OFG is the swelling of the upper/
lower lip, usually acute and painless (Figure 1A). It is intermittent in 
the early stages to become later persistent, but can also be recurrent 
or progressive.13 When the swelling is pronounced, the lip starts to 
fissure on the midline (median cheilitis) and at the buccal angles (an-
gular cheilitis). In addition to the typical labial involvement, OFG can 
affect oral cavity (mucosa of the cheeks, gums, palate, buccal floor, 
and tongue) as well as perioral, zygomatic, frontal, and eyelid regions 
(Figure 1B and C).14,15 Among the most common oral features, typi-
cal deep- oral ulcers, affecting the vestibular and lip mucosa, rarely 
tongue and palate, can be found. Swelling of the labial and buccal 
mucosa typically appears like "cobblestone." Edema can also affect 
the gums giving them a granular appearance (Figure 1D). In most 
severe OFG cases, painful latero- cervical lymphadenopathy can be 
present.
GCM was first described in 1945 as a rare disorder characterized 
by persistent swelling of one (usually the upper) or both (rarely) lips. 
The initial intermittent swelling generally resolves spontaneously. 
However, after several recurrences the swelling becomes chronic, re-
sulting in multiple granulomas, with aesthetic and functional deformi-
ties. Some patients report a burning sensation. Rarely, GCM appears 
TA B L E  1  Clinical features of our OFG patient cohort
Characteristics Patients
Number, n (%) 39 (100)
Males, n (%) 18 (46.2)
Age at diagnosis, years
Mean 45.3
SD 17.5
Age at onset, years
Mean 41.9
SD 17.3
OFG subtypes*, n (%)
MRS* 11 (28.2)
GCM* 11 (28.2)
Signs and symptoms, n (%)
Lip swelling (one/both) 38 (97.4)
Neurological symptoms 11 (28.2)
Atopy 14 (35.9)
Gastrointestinal symptoms 8 (20.5)
Oral aphthosis 7 (17.9)
Cervical lymphadenopathy 6 (15.4)
Parodontal disease 2 (5.1)
Allergy work- up, n (%)
Skin prick test 25 (64.1)
Positive 9 (36.0)
Patch test 18 (46.2)
Positive 5 (27.8)
Therapeutic options, n (%)
Oral steroids 20 (51.3)
Responders (partial or complete) 14 (70.0)
Intralesional steroids 12 (30.8)
Responders (partial or complete) 8 (66.7)
Anti- H1 drugs 10 (25.6)
Responders (partial or complete) 0 (0)
Biological drugs 8 (20.5)
Responders (partial or complete) 5 (62.5)
MRS is defined as OFG with neurological involvement.
GCM is defined as OFG with only lip involvement.
*OFG was diagnosed according to criteria listed in the Methods.
    |  2193GALDIERO Et AL.
in association with systemic symptoms such as malaise, fever, and/
or regional lymph node enlargement. Due to its rarity, GCM is quite 
neglected, with undefined incidence and prevalence.16 Most of the 
literature suggests an equal sex distribution, but a higher frequency 
in females is also reported. GCM usually appears between 20 and 
40 years of age and rarely affects children.16 Rare familial cases have 
been reported. This disorder is considered a subset of OFG or an 
incomplete variant of MRS. Indeed, GCM may be the onset sign of 
MRS, followed by the development of the neurologic symptoms in 
40% of cases.16
MRS is a rare neuro- mucocutaneous syndrome including orofa-
cial edema, facial nerve paralysis, and plicate tongue. These three 
clinical entities can be present all together (complete form) or not 
(mono- or oligo- symptomatic MRS).2 Symptoms usually appear in the 
second decade of life, without sex preference. The incidence is still 
unknown, and the diagnostic delay is estimated in about 10 years.17 
The onset of MRS generally occurs with the appearance of asym-
metric and non- itchy orofacial edema. Rarely, orofacial swelling can 
be associated with genital, circumscribed, non- painful edema. Facial 
nerve paralysis occurs suddenly, is localized on the same side of the 
facial edema, and is clinically not distinguishable from Bell's paral-
ysis.18 It can be bilateral, partial or total, recurrent (in about 70% 
of patients), and persistent. Involvement of other cranial nerves (tri-
geminal, hypoglossal, glossopharyngeal, olfactory, vestibular) has 
been reported, leading to dysphagia, dysarthria, altered vision, and 
impaired eye motility.19 If the fifth cranial nerve is affected, there 
can be hyperesthesia and migraine, or even damage to chewing mus-
cles ("masticatory atonia") with limited mouth opening.20 In this case, 
the finding of normal serum creatine kinase (CK) levels suggests that 
the damage is not attributable to myositis, but to muscular paralysis 
due to nerve inflammation instead.20






N° % N° %
Intralesional steroids 12 30.8 Triamcinolone 
acetonide
40 mg/ml at 1- to 4- wk 
intervals
3– 12 mo 8 66.7
Oral steroids 20 51.3 14 70
10 50 Prednisone 15– 60 mg/d 3– 6 mo 5 50
5 25 Betamethasone 1– 2 mg/d 3- to 7- d cyclic 
administration
5 100
2 10.0 Deflazacort 15 mg/d 3– 6 mo 1 50
cDMARDs 6 15.4
3 50 Methotrexate 7.5– 15 mg/wk 6– 12 mo 3 100
3 50 Sulfasalazine 1– 2.5 g/dk 8– 12 mo 0 0
Biologics 8 20.5
2 25 Infliximab 5 mg/kg at 8- wk intervals 1– 4 yrs 1 50
4 50 Adalimumab 40 mg at 2- wk intervals 3– 6 mo 3 75
1 12.5 Omalizumab 300 mg at 4- wk intervals 6 mo 1 100
1 12.5 Sarilumab 200 mg at 2- wk intervals 3 mo 0 0
Antihistamines 10 25.6
4 40 Cetirizine 10 mg/d 1– 3 mo 0 0
3 30 Rupatadine 10 mg/d 1– 3 mo 0 0
1 10 Ebastine 10 mg/d 1– 3 mo 0 0
Others
Clarithromycin 1 2.6 Clarithromycin 500 mg bid 5- to 7- day cyclic 
administration
1 100
Minocycline 2 5.1 Minocycline 100 mg/d 1 mo 1 50
Doxycycline 2 5.1 Doxycycline 100 mg/d 3 mo 1 50
Montelukast 1 2.6 Montelukast 10 mg/die 2 mo 0 0
Tranexamic Acid 1 2.6 Tranexamic Acid 1500 mg/die 1 mo 0 0
Surgery 2 5.1 2 100
Abbreviations: bid, twice a day; cDMARDS, conventional DMARDS; d, day; mo, month; wk, week; yrs, years.
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4.2  |  Pathogenesis, histological aspects, and 
differential diagnosis
The pathogenesis of the OFG is still unknown although a number of 
mechanisms have been hypothesized, including genetic predisposi-
tion, infectious, allergic, or immunological genesis.2,3,21- 23 The most 
common triggers for lip swelling are trauma and infections, but 
these are typically characterized by transient swelling.1 The more 
persistent aspect of OFG can be mimicked by a number of differ-
ent entities, summarized in Table 3. In particular, CD and sarcoido-
sis need to be carefully investigated.4,6,7,24,25 Currently, there is no 
consensus on the consideration of OFG as an independent clinical 
entity from or an oral manifestation of CD. In our patient cohort, 
fecal calprotectin measurement and abdominal US were performed 
in all patients, even in asymptomatic patients. Endoscopy was re-
served to patients referring gastrointestinal symptoms. Further 
studies are needed to better clarify the relationship between OFG 
and CD.8 In some cases, the intestinal involvement can be pauci- 
symptomatic compared with the oral manifestations and CD can be 
then diagnosed only following an intensive screening.5 Therefore, 
underestimation of CD in our patient cohort could be due to the 
short follow- up of these patients. To this aim, an extensive clinical 
investigation of digestive and extra- digestive signs of CD is needed. 
A multi- disciplinary approach, involving a gastroenterologist, is 
advisable, and in selected cases, endoscopy with biopsy might be 
performed.
Histological analysis is useful, above all for incomplete forms of 
OFG, and is part of the differential diagnosis with other granuloma-
tous disorders including cutaneous tuberculosis (TB), leishmaniasis, 
and leprosy, particularly in endemic areas.16 The OFG- affected tis-
sue typically shows sub- epithelial edema, increased number of di-
lated lymphatic vessels, granulomatous infiltrate and non- necrotic, 
non- caseous granulomas with lymphocytes in the center and large 
epithelioid cells on the periphery with or without multinucleated 
giant cells, perivascular mononuclear infiltration, in some cases with 
local fibrosis.26 The edema is due to the lymphatic and vascular de-
struction by granulomas, with subsequent vascular inflammation. A 
typical histopathological examination of a lip biopsy from a MRS pa-
tient of our cohort is illustrated in Figure 2. These histopathological 
features are not always observed, and their absence should not for-
mally exclude the diagnosis.16 In our OFG patient cohort, histological 
evaluation was available for 87.2% of patients, and in 73.5% of them, 
non- caseous granulomas were found. In the remaining 26.5%, chronic 
inflammation was described, without striking elements. As already 
mentioned, there is no consensus about the usefulness of biopsy for 
diagnostic purposes, and in particular for the complete form of MRS, 
in which the diagnosis has often been merely clinical. This appears 
as a very confounding aspect and makes diagnosis non- univocal. In 
our opinion, however, histopathological analysis is always necessary 
to complete diagnosis and to exclude differential diagnostic alterna-
tives, in particular infectious diseases. Although the histopathological 
features are not exclusive or specific for OFG, they strongly support 
the diagnosis.
In a Chinese case series of 16 patients with facial palsy in 
MRS, familial history was positive in about one third of the pa-
tients (31.3%).27 However, none of the patients of our cohort 
presented familial history. In some cases, neuroimaging is helpful 
to identify edema and thickening of facial soft tissues, as well 
as inflammation of the cranial nerves. Encephalic computed to-
mography (CT) and/or magnetic resonance (MR) can support the 
diagnosis and exclude other diseases. Some studies reported in-
creased levels of IgG into cerebrospinal fluid and serum of MRS 
patients, suggesting a possible immunological pathogenesis of 
the syndrome.
Apical periodontitis has been described in association with 
OFG.21 In our patient cohort, periodontitis was diagnosed in 2 
F I G U R E  1  Persistent lip swelling 
(A), fissured tongue (B– C), and gingival 
hypertrophy (D) in a young female patient 
with OFG
    |  2195GALDIERO Et AL.
out of 39 patients (5.1%), but not relevant benefit on OFG was 
obtained from its treatment. TB was ruled out in all patients, 
with the exception of one MRS patient with latent tuberculo-
sis. However, histopathological examination excluded TB and 
the OFG did not benefit from the anti- TB therapy. In our cohort, 
35.9% of the patients presented atopy, with food or inhalant 
sensitization. 15.4% of patients were positive for circulating an-
tinuclear antibodies even in the absence of clinical symptoms of 
autoimmunity. However, no clear pathogenic link was evident 
with these conditions, and only descriptive association can be 
made.
4.3  |  Therapeutic approaches
Although some rare spontaneous remissions have been described, 
most cases require one or more therapeutic agents. Several thera-
peutic strategies have been proposed, with no clear consensus. A 
summary of the published studies related to the therapeutic ap-
proaches is described in Table 4 and a summary of the therapeutic 
options used in our patient cohort is displayed in Table 2.
With regard to published data, restrictive diets were consid-
ered as first- line treatment, with good response to a cinnamon- and 
benzoate- free diet.28 Interestingly, patch tests were not useful in 
TA B L E  3  Differential diagnosis of OFG and its variants
Disease Differences from OFG
Crohn's disease Intestinal involvement (mainly of terminal ileum). Histological aspects indistinguishable from OFG.
Sarcoidosis Pulmonary, lymph node, cutaneous, salivary gland, neurological involvement. Rarely affects the oral cavity and lips
Histaminergic 
angioedema
Edema of the face, lips, tongue, larynx, or pharynx into a clinical picture of anaphylaxis. History of atopy. Antihistaminic drugs 
response. Identifiable trigger. Complete remission of symptoms between acute episodes
Hereditary 
angioedema
Complete remission of symptoms between acute episodes.
Cheilitis 
glandularis
Lip swelling with ulcers. Histology characterized by chronic inflammatory process, without granulomas, in minor salivary 
glands.




Necrotizing granulomatous vasculitis of small vessels involving the upper and lower respiratory tract and kidney. It can also 
involve other districts such as the oral cavity (typical picture of gingival hyperplasia and gingivitis with strawberry gums).
Behçet's 
disease
Chronic- relapsing systemic vasculitis of small, but also medium and large vessels. Typically characterized by relapsing 
aphthosis (minor or major ulcers and herpetic ulcers), associated with genital ulcers, ocular manifestations (anterior and 




Identifiable to polarized microscope observation.
Granulomatous 
rosacea
Clinical diagnosis based on the specific primary and secondary criteria.
Fungal infection Identification of pathogens with culture tests.
Leprosy Identification of Mycobacterium leprae by culture tests.
Mucocele Typical features distinguishable with imaging tests (CT, MR).







Typical features distinguishable with imaging tests (CT, MR) and histology.
Ascher 
syndrome
Congenital and characterized by the association of blepharochalasis and folding of the lip mucosa (usually upper) which 




Eyelid swelling associated with a thyroid dysfunction (hyperthyroidism).
Bell's palsy Absence of orofacial swelling and plicate tongue.
Morbihan 
syndrome
Chronic erythematous edema localized exclusively on the forehead, glabella, eyelids, and cheeks. It is considered a clinical 
variety or a complication of acne or rosacea
Trigeminal 
neuralgia
Absence of the MRS triad with pain as the dominant symptom.
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predicting the clinical response to the exclusion diet. Clinical im-
provement was evident within the first weeks. In absence of any 
significant improvement in 12 weeks, therapeutic alternatives were 
added and other allergens considered.28,29 Campbell et al. con-
ducted a study administering a diet without cross- reactive foods 
to patients with OFG and positive skin prick test (22 of 47 OFG pa-
tients) to silver birch, grass, mugwort, ragweed, and latex.30 Among 
the fourteen patients that completed the 12- week observation pe-
riod, two showed significant improvement and did not require any 
additional treatment.30 However, the small number of patients and 
the poor results suggest the uselessness of this approach in the cur-
rent clinical practice. In our cohort, no elimination diet was carried 
out with the single exception of the patient tested as positive to 
nickel by patch tests without, anyway, any clinical response. A per-
spective study with an extended allergy work- up by prick and patch 
test may better evaluate whether atopy plays a role in the patho-
genesis of OFG and validate the effectiveness of the exclusion diet.
Many medical therapeutic options have been described such 
as GCs, immunosuppressants (azathioprine, methotrexate, thalid-
omide, tacrolimus), anti- TB agents (ethambutol, isoniazid), antima-
larials (chloroquine), anti- leprosy drugs (clofazimine and dapsone), 
metronidazole, anti- TNF- α monoclonal antibodies (infliximab, 
adalimumab), sulfasalazine, antibiotics, and non- steroidal anti- 
inflammatory drugs (NSAIDs).1,2,7,12,25,26,28- 38
Among these therapeutic options, GCs are the most used. 
Intralesional administration is considered the best choice be-
cause of the possibility to release high concentrations of the 
drug in the affected site, overcoming the stratum corneum and 
avoiding local side effects such as atrophy and hypopigmenta-
tion.26,33,39 Usually, triamcinolone acetonide 10– 40 mg/ml is 
used, in multiple affected sites for 2– 3 weeks.26 Intralesional 
administration once a week for 3 weeks (one cycle) also showed 
a decrease in disease severity scores at all post- treatment 
time points.33 Intralesional triamcinolone acetonide was also 
administered in 12 out of 39 patients in our cohort, with good 
clinical result in more than 60%.
Systemic GCs with or without immunosuppressive agents can be 
used and show benefit on ulcers but less frequently on labial swell-
ing and often a recurrence is observed after suspension.1,25 In our 
cohort, systemic GCs were used in 51.3% of patients, with variable 
clinical response. Interestingly, all the 6 patients positive for the an-
tinuclear antibodies displayed a good or partial clinical response to 
oral or intralesional GCs, suggesting that, even in the absence of any 
clinical history, autoimmunity should always be evaluated in OFG 
patients and that the presence of antinuclear autoantibodies could 
support the use of GCs. However, GC indication in OFG is limited 
by the paucity of available studies. Wider studies on large scale are 
needed to further clarify this aspect.
Interestingly, in a cohort of patients suffering from OFG alone 
compared to patients suffering from OFG and CD,40 all treated with 
azathioprine (AZA), the proportion of patients responding to AZA 
with a diagnosis of CD/OFG was significantly higher compared to 
patients with OFG only. Factors predicting a need for AZA included 
a diagnosis of intestinal CD, sulcal swelling, sulcal ulcers, and upper 
lip involvement. The factor predicting response to treatment was a 
diagnosis of CD at 12 months of follow- up.40
The management of the facial nerve paralysis in the course of 
MRS is usually based on cycles of group B vitamin complex and 
systemic GCs.22,41,42 For frequent and progressive facial paralysis 
unresponsive to medical therapy, an alternative is the surgical de-
compression of the facial nerve, which was not needed by any of the 
patient of our cohort.43,44 Acupuncture and physical therapies were 
also reported.41
In a pediatric cohort of OFG patients treated with exclusive en-
teral nutrition using amino acid formula, good clinical response was 
shown to 6 weeks.7 Effective use of low- level laser was described in 
a case of OFG with good clinical response.35 Azithromycin was also 
used without clinical improvement.31 Surgical cheiloplasty remains 
F I G U R E  2  Histopathological 
examination of an incisional biopsy 
taken from the upper lip of patient with 
MRS showing chronic inflammatory 
infiltrates of submucosa and a small 
granuloma (arrow), consisting of 
lymphocytes, histiocytes, and epithelioid 
cells. The granulomas are shown at high 
magnification (400×) in the inset]
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Barry et al. (2005) GCM 1 Infliximab Good response
Gaya et al. (2006) GCM 1 Adalimumab Good response
Kauzman et al. (2006) OFG 2 Penicillin and antihistamines No Response
Intralesional triamcinolone 40 mg/ml Good response
OFG+CD Systemic GCs Partial response
Kakimoto et al. (2007) MRS 1 Infliximab Good response
Peitsch et al. (2007) GCM 1 Infliximab Good response
Ozgursoy et al. (2009) MRS 3 Systemic or intralesional GCs Good response
Oudrhiri et al. (2012) MRS 1 Intralesional betamethasone and doxycycline Good response
Ruiz Villaverde (2012) GCM 1 Adalimumab Good response
Campbell et al. (2013) OFG 22 Cinnamon- and benzoate- free diet, avoiding 
additional allergens
Good response in 2 out of 22
Elias et al. (2013) MRS 9 Oral prednisone, metronidazole, intralesional 
GCs
Good response
Liu et al. (2013) MRS 7 Systemic GCs Good response
Ravindran (2013) OFG 1 Intralesional triamcinolone + clobetasol Partial response
Ruozhouo Liu (2013) MRS 7 Systemic GCs, group B vitamins, acupuncture, 
physical therapy
Good response of facial palsy, 
no response of fissured 
tongue
Fedele et al. (2014) OFG 22 Intralesional GCs Good response
Shui feng et al (2014) MRS 44 Decompression facial nerve, systemic steroids, 
group B vitamins, physical therapy
Good response
Simonsen et al. (2014) OFG+CD 2 Infliximab Good response
OFG Topical GCs Good response
Stein et al. (2014) MRS 1 Adalimumab Good response
Vishwanath et al. 
(2014)
OFG 1 Intralesional triamcinolone Good response
Zulin Tan et al. (2014) MRS 15 Facial nerve decompression (9 patients) Good response
Prednisolone 1 mg/kg/d (6 patients) Partial response
Jasinska et al. (2015) MRS+MCTD 1 Chloroquine Good response
Kuok et al. (2015) MRS 1 Oral GCs Partial response
Lazzerini et al. (2015) OFG+CD 5 Oral prednisone 2 mg/kg/d No response
Infliximab + thalidomide 100 mg/d Good response
Oral GCs, antibiotics No response
Thalidomide Good response
Infliximab, oral steroids No response
GCs + AZA No response
Mentzer et al. (2015) OFG 60 AZA Good response
Tan et al. (2015) MRS 9 Facial nerve decompression Good response
Mutalib et al. (2016) OFG 10 6 weeks EEN + maintenance therapy Good response
OFG+IBD 19 Systemic GCs (4 patients) NA
Intralesional GCs (1 patient) NA
Targeted exclusion diet (2 patients) NA
6 weeks EEN (12 patients) Good response
Badshah et al. (2017) GCM 1 Infliximab Good response
Innocenti et al. (2017) GCM 1 Cheiloplasty+infliximab Good response
(Continues)
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the only effective solution for unresponsive cases,11 and also in our 
patient cohort, it gave good results in two patients.
Interestingly, based on the increased circulating levels of total IgE 
even in absence of a personal history of allergy, one patient of our 
cohort was treated with omalizumab with good clinical response as 
also recently reported.10 It was suggested that the effect of omali-
zumab was due to its anti- inflammatory effects as down- regulating 
the inflammatory cytokines IL- 2 and IL- 13. The local reduction in IL- 2 
in OFG lesions could be responsible for the down- regulation of IL- 2 
receptors on lymphocytes and the suppression of the inflammatory 
process.45 Quite recently, the case of a patient with GCM coinciding 
with CSU- related recurrent angioedema was reported, successfully 
treated with dapsone and omalizumab.46 These two were the only re-
ports describing the use of omalizumab in OFG. Further studies on a 
large scale are needed to confirm this therapeutic effect and to better 
understand the mechanisms of action of anti- IgE monoclonal anti-
body in OFG. Isolated case reports describe the usefulness of anti- 
TNF- α agents in OFG.12,32,34,36- 38,47 In our cohort, two patients were 
treated with infliximab and three with adalimumab (12.8%). Only one 
patient did not show benefit, whereas one complete and three par-
tial remissions were obtained, suggesting that anti- TNF- α strategy 
may be an efficient therapeutic alternative in non- responsive OFG 
patients. By contrast, in a refractory case, the anti- IL- 6 monoclonal 
antibody sarilumab was used, with inconclusive results.
5  |  CONCLUSIONS
In this report, we describe the clinical and therapeutic features of 
the first and largest OFG patient cohort described in Italy so far. 
Numerous reports have been published but are limited to case re-
ports and small case series, with low evidence.
Efforts are needed to approach the following crucial points.
First, OFG and its variants are still neglected diseases with un-
known etiology and pathogenesis. Our study highlights many unmet 
needs for the correct management of this disease. In the absence of 
an accepted classification, different variants of OFG are not uniquely 
identified. A clear OFG classification shared by the international sci-
entific community is mandatory to correctly interpret the data that 
will be collected in the future studies.
Second, patients with OFG remain a challenge in clinical prac-
tice. Our data show that the diagnostic work- up is differently ap-
proached based on the single- center experience; in particular, the 
need of a histological confirmation of OFG diagnosis is a knot to 
untie.
As a third point, although different therapeutic approaches are 
available, no predictive biomarkers, diagnostic criteria, or severity 
scores are available to orientate the therapeutic choice. The het-
erogeneity of therapeutic approaches observed in our cohort is due 




Jovan Lalosevic (2017) OFG 1 Azithromycin, topical GCs No response
Dexamethasone (1 mg/kg/die for a 3- day 
pulse)
Good response
Atkin et al. (2018) OFG 5 Azithromycin 500 mg/die for 3 days/week No response (only short term 
benefit)
De Moll et al. (2018) MRS 1 Adalimumab Good response
Espinoza et al. (2018) OFG 2 Cinnamon- and benzoate- free diet, avoiding 
additional allergens
Good response
Georgesen et al. (2018) OFG+CD+erythema 
multiforme
1 Oral GCs, antibiotics Good response but relapse
Methotrexate + valacyclovir Good response
Kosovali et al. (2018) MRS 1 Systemic GCs Good response
Maaz B. Badshah 
(2018)
OFG 1 Infliximab Good response
Marttala et al. (2018) OFG+CD 1 Cinnamon- and benzoate- free diet combined 
with periodontal prophylaxis
Good response
Nettis et al. (2018) GCM 1 Omalizumab Good response
Cancian et al. (2019) MRS 1 Antihistamines No response
Montelukast No response
Tranexamic acid No response
Prednisone 25 mg/die progressively tapered 
over few weeks or over few days
Partial response
Jacome- santos et al. 
(2019)
OFG 1 Low- level laser Good response
Abbreviations: AGCM, granulomatous cheilitis of Miescher; AZA, azathioprine; CD, Crohn's disease; EEN, exclusive enteral nutrition; GCs, 
glucocorticoids; MCTD, mixed connective tissue disease; MRS, Melkersson- Rosenthal syndrome; OFG, orofacial granulomatosis; NA, not available.
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strategy: Development of controlled studies to properly treat OFG- 
related disability should be a goal for the future.
Finally, early diagnosis is pivotal to improve the patient quality 
of life and perspectives. In some cases, a misdiagnosed OFG can sig-
nificantly impair the quality of life of the patients, due to aesthetic 
concerns, painful oral ulcerations, and additional symptoms such as 
neurological involvement.
We suggest that international registries should be created 
to enrich and share information between the different centers 
and endorse diagnostic and therapeutic guidelines. In this view, 
to improve our knowledge about this disease, we are currently 
working on a centralized informatics database aimed to pro-
viding the best diagnostic and treatment guidance for medical 
practice.
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